Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03026556 · ClinicalTrials.gov registry record
The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 42,534
- Enrollment target
NCT03026556 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 42,534 participants.
The verdict
NCT03026556 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 42,534 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of newly initiated dabigatran among patients diagnosed with non valvular atrial fibrillation (NVAF) in comparison to newly initiated rivaroxaban users and newly initiated apixaban users
Interventions
- DRUG Dabigatran vs. Rivaroxaban
- DRUG Dabigatran vs. Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42,534 participants |
| Start Date | 2016-12-29 |
| Est. Completion | 2017-08-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03026556
The ClinicalTrials.gov registry entry for NCT03026556 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42,534 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dabigatran vs. Rivaroxaban is the first listed.
NCT03026556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03026556 about?
NCT03026556 is a clinical study titled "The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis". The purpose of this study is to assess the safety and effectiveness of newly initiated dabigatran among patients diagnosed with non valvular atrial fibrillation (NVAF) in comparison to newly initiated rivaroxaban users and newly initiated apixaban users
What is the current status of trial NCT03026556?
This trial is currently completed. The enrollment target is 42,534 participants. The study started on 2016-12-29. Estimated completion is 2017-08-23.
What interventions are being tested in trial NCT03026556?
The interventions under investigation include: Dabigatran vs. Rivaroxaban (DRUG), Dabigatran vs. Apixaban (DRUG).
Who is sponsoring clinical trial NCT03026556?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.